We are live on ! Find out more
LPC

Lion Point Capital Portfolio holdings

AUM $16.7M
1-Year Est. Return 119.35%
This Fund
S&P 500
This Quarter Est. Return
+17.47%
1 Year Est. Return
+119.35%
3 Year Est. Return
+204.43%
5 Year Est. Return
+220.32%
10 Year Est. Return
+1,396.08%
AUM
$14.7M
AUM Growth
-$947K
Cap. Flow
-$1.92M
Cap. Flow %
-13.07%
Top 10 Hldgs %
74.34%
Holding
21
New
–
Increased
–
Reduced
1
Closed
2

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$1.52M
2
BLUE
bluebird bio
BLUE
+$385K
3
SPRB
Spruce Biosciences
SPRB
+$21.8K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FENC icon
1
Fennec Pharmaceuticals
FENC
$353M
$1.62M 11.03%
195,700
– –
ARDX icon
2
Ardelyx
ARDX
$1.25B
$1.31M 8.93%
335,400
– –
KNSA icon
3
Kiniksa Pharmaceuticals
KNSA
$4.83B
$1.27M 8.62%
45,900
– –
BBIO icon
4
BridgeBio Pharma
BBIO
$16.4B
$1.12M 7.62%
26,000
– –
INSM icon
5
Insmed
INSM
$22.9B
$1.07M 7.28%
10,650
-19,850
-65% -$1.52M
MLYS icon
6
Mineralys Therapeutics
MLYS
$2.34B
$1.07M 7.26%
79,000
– –
MIST icon
7
Milestone Pharmaceuticals
MIST
$146M
$1.06M 7.23%
548,806
– –
AVDL
8
DELISTED
Avadel Pharmaceuticals
AVDL
$873K 5.93%
98,700
– –
JSPR icon
9
Jasper Therapeutics
JSPR
$23M
$813K 5.52%
146,500
– –
BNTC icon
10
Benitec Biopharma
BNTC
$394M
$725K 4.93%
62,000
– –
GERN icon
11
Geron
GERN
$911M
$705K 4.79%
500,000
– –
ARQT icon
12
Arcutis Biotherapeutics
ARQT
$3.35B
$649K 4.41%
46,300
– –
IRON icon
13
Disc Medicine
IRON
$2.82B
$561K 3.81%
10,600
– –
SNDX icon
14
Syndax Pharmaceuticals
SNDX
$1.83B
$515K 3.5%
55,000
– –
RGNX icon
15
Regenxbio
RGNX
$617M
$474K 3.22%
57,750
– –
BHVN icon
16
Biohaven
BHVN
$2.1B
$320K 2.17%
22,700
– –
MRSN
17
DELISTED
Mersana Therapeutics
MRSN
$191K 1.29%
25,760
– –
MCRB icon
18
Seres Therapeutics
MCRB
$48.8M
$189K 1.29%
17,038
– –
HUMA icon
19
Humacyte
HUMA
$169M
$175K 1.18%
83,500
– –
BLUE
20
DELISTED
bluebird bio
BLUE
– –
-78,912
Closed -$385K
SPRB
21
Spruce Biosciences
SPRB
$115M
– –
-1,000
Closed -$21.8K

Similar funds

PA
PPM America Chicago, Illinois $16.6M AUM 31.99% 1-Year Est. Return
PA
Prossimo Advisors San Luis Obispo, California $16.4M AUM 14% 1-Year Est. Return
SR
Swiss Re Zurich, Switzerland $16.4M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
SRA
Summit Rock Advisors New York $16M AUM
CP
Covalent Partners Concord, Massachusetts $17.6M AUM 2.91% 1-Year Est. Return
B
BP London, United Kingdom $17.7M AUM 12.34% 1-Year Est. Return
CVV
Curative Ventures V Dallas, Texas $15.6M AUM 52.53% 1-Year Est. Return

Lion Point Capital's Q2 2025 Portfolio in Review

As of Q2 2025, Lion Point Capital held 21 positions worth $14.7M, down 6% from $15.7M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Lion Point Capital withdrew a net $1.92M in Q2 2025, closing 2 positions and reducing 1 holding. Its most notable exit was bluebird bio, an estimated $385K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Lion Point Capital's biggest Q2 2025 reduction was Insmed, cutting an estimated $1.52M.
  • Lion Point Capital fully exited bluebird bio in Q2 2025, selling an estimated $385K.
  • Lion Point Capital's ten largest holdings make up 74% of its $14.7M portfolio in Q2 2025.
  • Lion Point Capital opened 0 new positions and closed 2 in Q2 2025.
  • Lion Point Capital's portfolio value fell 6% quarter-over-quarter to $14.7M.

Based on Lion Point Capital's 13F filing for Q2 2025, filed 14 Aug 2025.